Regulus Therapeutics Inc (NASDAQ:RGLS) does about 1.83M shares in volume on a normal day but saw 3074894 shares change hands in the recent trading day. The company now has a market cap of 519.98M USD. Its current market price is $7.85, marking no change compared to the previous close of $7.85. The 52 week high reached by this stock is $8.20 whilst the lowest price level in 52 weeks is $0.83.
Regulus Therapeutics Inc (RGLS) has a 20-day trading average at $3.05 and the current price is -4.27% off the 52-week high compared with 845.67% distance from its 52-week low. The 50-day simple moving average of the closing price is $2.08 and its 200-day simple moving average is $1.65. If we look at the stock’s price movements over the week, volatility stands at 11.55%, which decreases to 10.88% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 92.65 to suggest the stock is overbought.
The consensus objective for the share price is $8.80, suggesting that the stock has a potential upside of 10.8% over the period.
FactSet Research has provided data showing that 1 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 1 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Moderate Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on March 27, 2025 when Wells Fargo upgraded the stock to “Overweight” and issued a price target of between $3 and $6. Leerink Partners initiated its price target at $6.
The current price level is 157.65%, 278.08%, and 375.09% away from its SMA20, SMA50, and SMA200 respectively, with the RGLS price moving below the 50-day SMA on current market day. Regulus Therapeutics Inc (RGLS) stock is up 184.42% over the week and 300.51% over the past month. Its price is 396.84% year-to-date and 241.30% over the past year.
To reach the target analysts have set, the stock logically needs to grow 10.8 percent from here.
Outstanding shares total 65.50M with insiders holding 2.51% of the shares and institutional holders owning 82.89% of the company’s common stock. The company has a return on investment of -60.45% and return on equity of -95.00%. The beta has a value of 0.39. Price to book ratio is 6.73.
